When does a broken growth signal stop being the main problem? How does one gene mutation teach neurons to keep shouting after the original alarm should have faded? Why would a drug that hits mTORC1 still fail to quiet hyperactive cells? And most unsettling of all - is the really important clock in tuberous sclerosis set absurdly early, while the brain is still assembling its wiring with the grace of a caffeinated watchmaker?

A new Cell Reports paper tackles exactly that problem in tuberous sclerosis complex, or TSC, a genetic disorder caused by variants in TSC1 or TSC2. Those genes normally help restrain mTORC1, a major growth-control pathway. When that brake fails, cells lean into growth mode. In the brain, that can mean epilepsy, developmental differences, and the kind of neural overexcitement that makes circuits behave like someone glued the accelerator to the floor [1].

Not Just a Stuck Gas Pedal

The usual story in TSC goes like this: mTORC1 is too active, so block mTORC1. Fair enough. That logic has already produced useful drugs such as everolimus, which can help some people with TSC, especially for seizures and tumor-related problems [2-4]. But brains are not toasters. You do not swap one fuse and call it character growth.

This new study argues that early mTORC1 overactivity does something sneakier. It changes the transcriptional program of neurons - the pattern of which genes they turn on when they mature and fire. In TSC2-deficient excitatory neurons, the authors found lower levels of EGR1, an activity-dependent transcription factor. Think of EGR1 as one of the first scribes to show up when neurons start working hard. If that scribe clocks in late, or never gets the memo, the rest of the molecular paperwork can go sideways fast [1].

The Epigenetic Paper Jam

Here is the sharper twist. The paper links that transcription problem to disrupted DNA demethylation during neuronal maturation. DNA methylation is one of the chemical systems cells use to mark what should be easier or harder to read from the genome. It is not a mystical destiny sticker. It is more like a set of tiny access permissions, because biology apparently wanted to reinvent bad office IT policies at the molecular scale.

In healthy developing neurons, some of those methylation marks shift as the cells mature and respond to activity. In the TSC models, that process did not unfold normally. The result was weaker activity-dependent gene expression. So the problem was not just that mTORC1 was revved up in the moment. The earlier mTORC1 problem seems to have altered the circuit's instruction manual while the parts were still being machined [1].

That idea fits a bigger trend in TSC research. Reviews in Lancet Neurology, Brain, Molecular Psychiatry, and Brain Communications all point to TSC as a disorder where timing matters enormously - especially during fetal life, infancy, and early childhood, when excitation, inhibition, axon growth, myelination, and network stability are all being tuned on a very unforgiving schedule [2-5].

Why Late Rescue May Miss the Train

The most clinically provocative result is also the most annoying one, which is usually a sign that science is doing its job. The researchers found that late mTORC1 inhibition in mature human neurons only partly corrected gene-expression changes and did not reduce spontaneous neuronal hyperactivity [1].

That does not mean mTOR inhibitors are useless. It means they may be solving only part of the machine, especially if treatment begins after key developmental windows have already passed. If early mTORC1 overactivity leaves behind a durable transcriptional and epigenetic footprint, then later treatment may be a bit like fixing the factory's power surge after the defective gears have already shipped.

That matters because TSC is already one of the best examples in neurology of why early detection could change outcomes. Clinical and translational work has pushed hard on pre-symptomatic monitoring, especially for seizure risk in infants, and advocacy groups keep emphasizing the same point: if you can identify high-risk children earlier, you may have a better shot at preventing some downstream damage instead of chasing it later [3,5].

The Bigger Deal

Why should you care if a transcription factor named EGR1 is having a rough day in lab-grown neurons? Because this is how the field inches from "pathway overactive" to "here is the lasting molecular scar it leaves, and here is when it forms." That is a much more useful map.

If these findings hold up, they push TSC treatment thinking in two directions at once. First, intervene earlier, before hyperactive signaling hardens into long-lived circuit changes. Second, combine mTOR-focused therapy with treatments aimed at transcription, epigenetic state, or network excitability itself. In other words, if the Rube Goldberg machine of brain development has already launched the marble, tipped the spoon, and set the tiny cymbal monkey loose, you may need more than one hand on the apparatus.

The paper does not promise a miracle. It does something better. It tightens the timing diagram. And in a disease where milliseconds grow into years, that may be exactly the sort of precision the field needs.

References

1. Afshar-Saber W, Ruiz JF, Gisser I, et al. Neuronal hyperactivity becomes mTORC1 independent due to transcriptional changes in tuberous sclerosis complex disease models. Cell Reports. 2025;44(12):116664. DOI: 10.1016/j.celrep.2025.116664
2. Curatolo P, Moavero R, de Vries PJ. Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy. Lancet Neurology. 2022. DOI: 10.1016/S1474-4422(22)00213-7
3. Moavero R, et al. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy. Brain. 2023;146(7):2694-2710. DOI: 10.1093/brain/awad048
4. Karalis V, Wood D, Teaney NA, et al. The role of TSC1 and TSC2 proteins in neuronal axons. Molecular Psychiatry. 2024;29:1165-1178. DOI: 10.1038/s41380-023-02402-7, PMCID: PMC12863650
5. Moloney PB, Cavalleri GL, Delanty N. Epilepsy in the mTORopathies: opportunities for precision medicine. Brain Communications. 2021;3(4):fcab222. DOI: 10.1093/braincomms/fcab222

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.